ViroVet
PrivateLast Round
Series C
Jun 16, 2022
Total Funding Raised
$14.36M
Company Overview
ViroVet is a biopharmaceutical company that develops innovative technologies, including antiviral drugs and vaccines, for the control of viral diseases in livestock.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ViroVet Comps
Public and private peers based on sector, stage, and business model.
ViroVet Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 16, 2022 | ||||
| Series B | May 28, 2020 | ||||
| Grant | Sep 1, 2018 | ||||
| Series A Extension | Oct 4, 2017 | ||||
| Series A | Jan 10, 2017 |
Key People
Founding team and executive leadership
ViroVet Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Capricorn Partners | Series B, Series C |
| KU Leuven | Series B |
| PMV | Series B, Series C, Series A |
| Seventure Partners | Series C, Series B |
ViroVet Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ViroVet's valuation, stock price, and market status.
